secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2022-12-07T23:59:59+00:00
Accession:  0001193125-22-300219
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience amends bylaws to revise director nomination procedures and conform to Delaware law
--------------------------------------------------------------------------------

- Board amended and restated bylaws effective Dec 6, 2022, adding requirement for stockholders to deliver Rule 14a-19 compliance evidence 5 business days before meeting.
- Revised procedures for stockholder director nominations and proposals to align with recent DGCL amendments.
- Updated provisions regarding directors, Board committees, and officers; made ministerial and clarifications changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522300219/0001193125-22-300219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522300219/d431885d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-300219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer